Drug Discovery
Custom Pages


The company has R&D operations and management teams in Guangzhou, China and San Francisco, USA. It has 500 square meters of experimental and office space, with 10,000-class cell rooms and SPF-class animal rooms, which can carry out in vivo and in vitro experiments. The company also makes full use of high-quality CRO companies for pre-clinical testing and GMP drug production.

The Platform

Fundamental Biology

CGX1321 is a novel WNT pathway inhibitor. Through inhibition of Porcupine in WNT secreting cells, CGX1321 has specific anti-cancer effects on tumors with RSPO gene fusion and RNF43 gene mutation.

Curegenix is a clinical-stage company with operations in the San Francisco Bay Area and Guangzhou China. We focus on the discovery and development of novel drugs.

Get In Touch with Curegenix

    Copyright 2021 Curegenix Corporation | All Rights Reserved